We congratulate Cheung et al. on their study assessing the impact of diabetes and hyperglycaemia on outcomes in those hospitalised with coronavirus disease 2019 (COVID-19) during the 2021 New South Wales outbreak. 1 It is worth drawing attention to this report as the latest to show that diabetes and hyperglycaemia are not associated with higher inpatient COVID-19 mortality in nonsurge, higherresourced health care settings, thus illustrating two important points: that the earlier understanding of diabetes-related risk was not shown later in the pandemic, and that time-and context-specific data generated during an evolving situation such as a pandemic may not apply more broadly.Initial reports and meta-analyses conducted early in the COVID-19 pandemic found diabetes and hyperglycaemia to be associated with increased rates of adverse in-hospital outcomes, including mortality. 2,3 These largely Chinese and Western European reports arose from early 2020 when experience with COVID-19 management was nascent and health care services were frequently overwhelmed.By contrast, reports from Melbourne, Australia, and the Bay Area of Northern California, United States, later in 2020 found no adjusted association between diabetes, hyperglycaemia and in-hospital mortality in patients admitted with COVID-19, consistent with Cheung et al.'s findings. 4,5 This lack of an association holds despite differing specific contexts such as the Melbourne outbreak including many cases acquired in residential aged care facilities, and a different selection of covariates adjusted for in multivariable models.As noted by the author groups, differences between these studies and early reports include: (i) the nonsurge nature of the local outbreaks in higher-resources settings; (ii) availability of specific COVID-19 therapies including